Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

HomeAlle NewsMeistgelesene ArtikelBusiness Leaders Biografien 
Übersicht 
Rory Balfour Riggs is an entrepreneur and businessperson who founded 12 companies, including: Royalty Pharma Plc, FibroGen, Inc. and StageZero Life Sciences Ltd. and who has been at the helm of 15 different companies. Currently, Mr. Riggs is Chairman & Chief Executive Officer for Cibus Corp. (which he founded in 2001), Chairman of Cibus US LLC (which he founded in 2001), Chairman of Cibus Ltd. and Chairman for Nucelis, Inc. (which are all subsidiaries of Cibus Corp.), Chief Executive Officer for Syntax Analytics LLC (which he founded in 2010), Chief Executive Officer of Locus Analytics LLC (which he founded in 2010), Chief Executive Officer for Syntax LLC (which he founded in 2010), Chief Executive Officer & Trustee at Syntax ETF Trust and Chief Executive Officer at Syntax Advisors LLC (which he founded) (both are subsidiaries of Syntax LLC), General Partner of Scientia Ventures LLC (which he founded in 2006) and Chairman at RP Management LLC (which he founded in 1996). Rory Balfour Riggs is also Managing Member at Balfour Venture Partners and on the board of 6 other companies.

He previously held the position of Managing Member at Balfour LLC, Director at eReceivables LLC (he founded the company in 2003), President & Chief Executive Officer at The RF&P Corp., Associate of Strategic Planning Associates, President, Chief Financial Officer & Director at Biomatrix, Inc., Managing Member at New Ventures I LLC, Managing Director at PaineWebber, Inc., Principal at Pacific Media Partners, Inc. and Independent Director at FibroGen, Inc.

Mr. Riggs received an undergraduate degree from Middlebury College and an MBA from Columbia Business School.


Aktuelle Stellungen und Verantwortungsbereiche Rory Balfour Riggs 
NameTitel Seit
Royalty Pharma plc
(Pharmazeutika)
Director 2020
Intra-Cellular Therapies, Inc.
(Biotechnologie)
Independent Director 2014
StageZero Life Sciences Ltd.
(Biotechnologie)
Independent Director 2013
Cibus Global, Ltd.
(Landwirtschaft und Fischfang)
Chairman & Chief Executive Officer 2021
Syntax Analytics LLC Chief Executive Officer 2010
Locus Analytics LLC Chief Executive Officer 2010
Syntax Advisors LLC Founder & Chief Executive Officer -
Syntax LLC Chief Executive Officer 2010
RP Management LLC Chairman 2003
Cibus Ltd. Chairman -
Nucelis, Inc. Chairman -
Syntax ETF Trust Chief Executive Officer & Trustee 2017
Cibus US LLC Chairman -
Patient Choice Healthcare, Inc. Director -
ITI, Inc. (New York) Director 2014
Nuredis, Inc. Director -
Balfour Venture Partners Managing Member -
Scientia Ventures LLC General Partner 2006


Anteile an Rory Balfour Riggs 
NameAktien%Bewertung
RPI US PARTNERS 2019 LP6 664 7043,12%278 651 274 USD
FibroGen, Inc. (FGEN)
(Biotechnologie)
1 001 4631,07%12 458 200 USD
Royalty Pharma plc (RPRX)
(Pharmazeutika)
291 7120,067%12 196 479 USD
Intra-Cellular Therapies, Inc. (ITCI)
(Biotechnologie)
77 3610,082%3 888 164 USD


Rory Balfour Riggs: Persönliches Netzwerk 
Meistgelesene News 
29.09.Buffetts Berkshire Hathaway kauft 5,99 Mio. weitere Occidental-Aktien
MR
26.09.Die Seifenoper von Unilever: M&A, Stellenabbau, Nelson Peltz im Vorstand
MR
30.09.Bei Fresenius und Dialysetochter FMC startet am Samstag neue Führunsspitze
DP
05.10.Musk sagt, der Twitter-Deal sei ein "Beschleuniger" für die Entwicklung einer "Alles-App".
MR
26.09.Twitter interviewt Elon Musk, der für seine kämpferischen Äußerungen bekannt ist
MR
28.09.Elon Musk will SEC-Zustimmung einschränken, Vorabgenehmigung von Tweets beenden
MR
29.09.Der lange, kurvenreiche Weg zum Porsche-Börsengang von Volkswagen
MR
04.10.Kreml findet Musk-Vorstoß 'positiv' - weist ihn aber im Kern zurück
DP
30.09.Zuckerberg bereitet Meta-Mitarbeiter auf Sparmaßnahmen vor
DP
03.10.Ukraine lehnt Friedensszenario von Milliardär Elon Musk ab
DP
Mehr Börsen-Nachrichten, Aktienanalysen und Empfehlungen


© 2022 People and Ownership :   
Rory Balfour Riggs : Verbindungen